Table 2.

Prescription pattern of drugs with cytochrome P450-inducing and -inhibitory properties and the proportion of relevant pharmacological interactions in Colombia

Drugs	Patients with inhibitors or inducers	%a	%b	Prevalencec	Patients with interactions	%d	Prevalencec
Cytochrome P450 inhibitors	40,744	64.4	100.0	26.5	12,225	30.0	8.0
Verapamilm	15,542	24.5	38.1	10.1	1774	11.4	1.2
Fluconazolm	14,944	23.6	36.7	9.7	5208	34.9	3.4
Amiodaronem	3246	5.1	8.0	2.1	1880	57.9	1.2
Ketoconazoles	2586	4.1	6.3	1.7	893	34.5	0.6
Diltiazemm	1855	2.9	4.6	1.2	1162	62.6	0.8
Clarithromycins	1274	2.0	3.1	0.8	698	54.8	0.5
Ciclosporinm	640	1.0	1.6	0.4	356	55.6	0.2
Darunavirs	231	0.4	0.6	0.2	44	19.0	<0.1
Erythromycinam	144	0.2	0.4	0.1	42	29.2	<0.1
Cobicistats (associated1)	125	0.2	0.3	0.1	25	20.0	<0.1
Imatinibm	99	0.2	0.2	0.1	13	13.1	<0.1
Itraconazoles	90	0.1	0.2	0.1	22	24.4	<0.1
Nilotinibm	68	0.1	0.2	<0.1	14	20.6	<0.1
Dronedaronam	48	0.1	0.1	<0.1	33	68.8	<0.1
Darunavir/ritonavirs	46	0.1	0.1	<0.1	5	10.9	<0.1
Ribociclibm	42	0.1	0.1	<0.1	1	2.4	<0.1
Darunavir/cobicistats	26	0.0	0.1	<0.1	12	46.2	<0.1
Voriconazoles	18	0.0	0.0	<0.1	13	72.2	<0.1
Posaconazoles	16	0.0	0.0	<0.1	7	43.8	<0.1
Ritonavirs	12	0.0	0.0	<0.1	6	50.0	<0.1
Atazanavir/ritonavirs	11	0.0	0.0	<0.1	11	100.0	<0.1
Lopinavir/ritonavirs	6	0.0	0.0	<0.1	3	50.0	<0.1
Aprepitantm	5	0.0	0.0	<0.1	0	0.0	<0.1
Atazanavirs	3	0.0	0.0	<0.1	1	33.3	<0.1
Crizotinibm	2	0.0	0.0	<0.1	2	100.0	<0.1
Isavuconazolm	2	0.0	0.0	<0.1	0	0.0	<0.1
Cytochrome P450 inducers	23,233	36.6	100.0	15.1	7872	33.9	5.1
Carbamazepines	18,874	29.8	81.2	12.3	6668	35.3	4.3
Phenytoins	2634	4.2	11.3	1.7	759	28.8	0.5
Phenobarbitals	1667	2.6	7.2	1.1	348	20.9	0.2
Bosentanm	142	0.2	0.6	0.1	26	18.3	<0.1
Enzalutamides	102	0.2	0.4	0.1	23	22.5	<0.1
Rifampicins (alone or associated)	49	0.1	0.2	<0.1	16	32.7	<0.1
Apalutamides	48	0.1	0.2	<0.1	4	8.3	<0.1
Etravirinam	42	0.1	0.2	<0.1	14	33.3	<0.1
Modafinilm	25	0.0	0.1	<0.1	1	4.0	<0.1
Primidones	18	0.0	0.1	<0.1	4	22.2	<0.1
Efavirenzm (alone or associated2)	31	0.0	0.1	<0.1	9	29.0	<0.1
Dabrafenibm	7	0.0	0.0	<0.1	0	0.0	<0.1
Mitotans	2	0.0	0.0	<0.1	0	0.0	<0.1
Lumacaftor/ivacaftors	1	0.0	0.0	<0.1	0	0.0	<0.1

^sStrong; ^mModerate; ¹Tenofovir/emtricitabine/elvitegravir; ²Tenofovir/emtricitabine or lamivudine

^aPercentage of patients with inhibitors or inducers calculated on total number of people (n = 63,433)

^bPercentage of patients with inhibitors or inducers calculated on all inhibitors (n = 40,744) or inducers (n = 23,233)

^cPrevalence per 1000 people with medication dispensing

^dPercentage of patients with interactions calculated on the totality of each inhibitor or inducer